Johnson & Johnson (NYSE:JNJ<\/a>) and Abbott Laboratories (NYSE:ABT<\/a>) both recently posted earnings that show two healthcare giants moving in opposite strategic directions. <\/p>\n JNJ is tightening its focus by spinning off Orthopaedics, while Abbott just closed a $21 billion Exact Sciences deal. The businesses behind these tickers look nothing alike right now. <\/p>\n Oncology Powers JNJ. Cancer Diagnostics Reshapes Abbott. <\/p>\n JNJ’s Q1 report leaned on its Innovative Medicine engine, with segment revenue of $15.43 billion, up 11.2%. DARZALEX brought in $3.96 billion (+22.5%), TREMFYA jumped 68.3%, and CARVYKTI kept scaling. That momentum is doing heavy lifting because STELARA collapsed 59.7% against biosimilars, a real drag that TREMFYA is fortunately absorbing. <\/p>\n Abbott’s Q2 story is different. Medical Devices delivered $5.85 billion, up 9%, led by FreeStyle Libre continuous glucose monitors at $2.19 billion. Diagnostics surged 42.3% almost entirely because Cologuard from Exact Sciences contributed $919 million. Strip that out and comparable sales grew a more modest 4.8%, which is less flashy but more representative. <\/p>\n CEO Joaquin Duato framed JNJ’s quarter as “a strong start to 2026”, citing approvals for ICOTYDE and VARIPULSE Pro. Abbott CEO Robert Ford was more forward-looking, saying results “reflect the momentum we are building” heading into H2.\u00a0 <\/p>\n Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Johnson & Johnson didn’t make the cut. Grab the names FREE today<\/a>. <\/p>\n Lens <\/p>\n JNJ <\/p>\n Abbott <\/p>\n Core Bet <\/p>\n Pharma innovation, cell therapy <\/p>\n Devices, glucose monitoring, cancer dx <\/p>\n Recent Strategic Move <\/p>\n Orthopaedics spin-off in 18 to 24 months <\/p>\n Closed $21B Exact Sciences deal <\/p>\n Key Vulnerability <\/p>\n STELARA biosimilar cliff <\/p>\n Nutrition weakness, CGM competition <\/p>\n Forward P\/E <\/p>\n 22 <\/p>\n 18 <\/p>\n JNJ is pruning. Abbott is stacking. <\/p>\n JNJ raised full-year revenue guidance to $100.3B to $101.3B and adjusted EPS to $11.45 to $11.65. Abbott lifted its EPS range to $5.45 to $5.60, though acquisition financing pushed interest expense to $299 million from $50 million. Digesting that debt is real work. <\/p>\n Story Continues <\/p>\n The Next Test Is Execution <\/p>\n For JNJ, I want to see whether TREMFYA and DARZALEX can keep outpacing the STELARA cliff, and whether the DePuy Synthes separation stays on schedule. <\/p>\n For Abbott, the Cologuard integration needs to produce durable margin expansion beyond the optical revenue lift. Nutrition remains a soft spot at down 3.1%, and Structural Heart U.S. slid 9.8%. Both issues are manageable but deserve close attention. <\/p>\n The stocks themselves have diverged sharply. JNJ is up 23.63% year to date, while Abbott is down 18.16%. That gap has already priced in a lot of the narrative. <\/p>\n Why I Lean JNJ Today, but Watch Abbott Closely <\/p>\n If you want stability, JNJ looks like the cleaner story to me right now. Oncology is compounding, the pipeline delivered multiple game-changing approvals this quarter, and the 64th consecutive year of dividend increases speaks to durability. The 2.1% yield is modest, but reliable. <\/p>\n That said, I think Abbott is the more interesting turnaround setup. Shares trade cheaper on forward earnings, the yield is higher at 2.51%, and if Cologuard integration delivers, sentiment could snap back quickly. <\/p>\n Abbott is unlikely to offer a smooth ride over the next two quarters, but for investors comfortable with post-acquisition messiness, the risk-reward profile looks fairer than the YTD chart suggests. On balance, JNJ screens as the ballast name here, with Abbott worth monitoring closely. <\/p>\n Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Johnson & Johnson didn’t make the cut. Grab the names FREE today<\/a>. <\/p>\n<\/a> Chinnapong \/ iStock via Getty Images <\/p>\n
<\/a> JNJ Earnings Explorer \u2014 24\/7 Wall St. <\/p>\n
<\/a> ABT Earnings Explorer \u2014 24\/7 Wall St. Narrowing the Portfolio vs. Widening the Net <\/p>\n